Alnylam Pharmaceuticals, Inc. has witnessed a significant rise due to multiple positive factors lately. They had outstanding performance in
Q2, 2024 beating both earnings and revenue estimates. The shares surged by 30% following the success of their drug for a Rare Heart Disease.
Analysts upgraded their price target numerous times, reaching up to $366 per share. There have also been positive phase III results for their heart disease drug,
vutrisiran, as well as promising estimates indicating the company may be trading below intrinsic value. Expansion of their partnership with
Medison Pharma for commercializing
RNAi Therapeutics in LATAM and APAC markets, including Australia, signifies their global outreach. However, some negative signals arose, including insiders disposing of their stock and fluctuations in their heart drug trial. Despite meeting their goals, these changes raised some doubts sinking shares temporarily. Nevertheless, the overall sentiment has been extremely positive, propelling the value of the company upwards significantly over the recent period.
Alnylam Pharmaceuticals News Analytics from Wed, 13 Dec 2023 08:00:00 GMT to Sun, 04 Aug 2024 13:59:16 GMT -
Rating 8
- Innovation 6
- Information 7
- Rumor -3
